Suchergebnisse - "Hayden, Frederick G"

PubPharm (362)

11

COVID-19, Influenza and RSV : Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference

enthalten in: Antiviral research | 2022

von McKimm-Breschkin, J. | Hay, A. | Cao, B. | +6

12

Influenza polymerase inhibitor resistance : Assessment of the current state of the art - A report of the isirv Antiviral group

enthalten in: Antiviral research | 2021

von Ison, M. | Hayden, F. | Hay, A. | +4

13

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

enthalten in: The Journal of infectious diseases | 2021

von Hall, M. | Anderson, J. | Anderson, A. | +39

14

Baloxavir Treatment in Adolescents With Acute Influenza : Subgroup Analysis From the CAPSTONE-1 Trial

enthalten in: Journal of the Pediatric Infectious Diseases Society | 2021

von Portsmouth, S. | Hayden, F. | Kawaguchi, K. | +5

15

Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances

enthalten in: Cold Spring Harbor perspectives in medicine | 2021

von Beigel, J. | Hayden, F.

16

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU : First Update

enthalten in: Critical care medicine | 2021

von Alhazzani, W. | Evans, L. | Alshamsi, F. | +44

CommentIn: Crit Care Med. 2022 Jan 1;50(1):e95-e96. - PMID 34407038

17

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

enthalten in: EBioMedicine | 2020

von Wang, Y. | Zhong, W. | Salam, A. | +29

18

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

enthalten in: Lancet (London, England) | 2020

von Cao, B. | Hayden, F.

CommentOn: Lancet. 2020 Oct 24;396(10259):1345-1352. - PMID 33031764

19

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome

enthalten in: The New England journal of medicine | 2020

von Arabi, Y. | Asiri, A. | Assiri, A. | +49

20

Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Infectious diseases | 2020

von Ison, M. | Portsmouth, S. | Yoshida, Y. | +5

CommentIn: Lancet Infect Dis. 2020 Oct;20(10):1112-1114. - PMID 32526194